CG Oncology Management
Management criteria checks 2/4
CG Oncology's CEO is Arthur Kuan, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $3.93M, comprised of 11.4% salary and 88.6% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $1.02M. The average tenure of the management team and the board of directors is 1.3 years and 6.2 years respectively.
Key information
Arthur Kuan
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 11.4% |
| CEO tenure | 7.9yrs |
| CEO ownership | 0.05% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Dec 13Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth
Oct 04
CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 25CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$79m |
| Mar 31 2024 | n/a | n/a | -US$72m |
| Dec 31 2023 | US$4m | US$449k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Dec 31 2022 | US$1m | US$394k | -US$44m |
Compensation vs Market: Arthur's total compensation ($USD3.93M) is about average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: Arthur's compensation has increased whilst the company is unprofitable.
CEO
Arthur Kuan (33 yo)
7.9yrs
Tenure
US$3,933,996
Compensation
Mr. Arthur Kuan serves as Chief Executive Officer and Director at CG Oncology, Inc. since 2017 and also serves as Chairman since December 2023. Mr. Kuan served as the Chief Operating Officer of CG Oncology...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.9yrs | US$3.93m | 0.053% $ 1.0m | |
| President & COO | 1.4yrs | US$3.03m | 0% $ 0 | |
| Chief Medical Officer | 1.3yrs | US$2.44m | 0.0019% $ 37.1k | |
| CFO & Secretary | less than a year | no data | 0.0030% $ 56.7k | |
| Vice President of Finance | 2.9yrs | no data | no data | |
| Chief Technical Officer | 1.3yrs | no data | no data | |
| General Counsel & Chief Compliance Officer | no data | no data | no data | |
| Vice President of Communications & Patient Advocacy | no data | no data | no data | |
| Vice President of Corporate Development | no data | no data | no data |
1.3yrs
Average Tenure
53yo
Average Age
Experienced Management: CGON's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.9yrs | US$3.93m | 0.053% $ 1.0m | |
| Lead Independent Director | 6.2yrs | US$77.54k | 0% $ 0 | |
| Independent Director | 1.4yrs | no data | no data | |
| Independent Director | 6.2yrs | US$198.00k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$599.04k | no data | |
| Independent Director | 9.1yrs | no data | 5.35% $ 102.4m | |
| Independent Director | 2.3yrs | no data | no data |
6.2yrs
Average Tenure
54.5yo
Average Age
Experienced Board: CGON's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:33 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CG Oncology, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Yang | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Corinne Johnson | Goldman Sachs |